ABN Amro Selects Temenos to Accelerate Continuous Innovation – ‘Coding in the Morning, Deploying in the Afternoon’
Temenos (SIX: TEMN), the banking software company, today announced that ABN Amro has selected Temenos Continuous Deployment, which utilizes DevOps principles and extends the Temenos DevOps operations into the banks environments, to accelerate the bank’s speed of software delivery and rapidly launch new competitive innovations to the market. With 22 innovation teams within the Investment and Corporate Banking division of ABN Amro using Temenos Continuous Deployment to support their agile development methodologies, the bank will be able to bring business change more rapidly and securely to market. Using Temenos Continuous Deployment, this repeatable process will be dramatically faster and more flexible and is expected to increase efficiency in early stage testing and deployment by more than 30%. Temenos Continuous Deployment is provided by Temenos as a Service (SaaS) while reducing cost of deployment.
Friso Westra, Head of IT Development Core Banking International at ABN Amro will be joining Max Chuard, CEO of Temenos on the opening plenary session at TCF to talk about using Continuous Deployment to accelerate innovation.
The banking group, one of the largest in the Netherlands and a longstanding customer of Temenos, is now taking advantage of the Temenos Continuous Deployment offering to enable developer teams to quickly and independently develop, test and deploy change including configuration and extension code in a safe, secure and reliable automated environment. ABN Amro will be able to provision a new environment to build and test its innovations in just hours. The number of deploy and test pipelines per day is expected to increase from 1 to 15 per day. The bank also envisages being able to increase test cycles by 100x, the increase in testing will result in higher quality, more frequent automated releases.
By enabling a “code in the morning, deploy in the afternoon” approach, the time required to develop, test and release software changes is reduced from weeks to days or hours, enabling the bank to rapidly deploy change in a safe and controlled manner. Temenos Continuous Deployment offers a self-service environment where the project team can simply and quickly request on-demand the creation and provisioning of production-like environments based on the bank’s configuration. It allows automated testing and deployment of software changes from both the bank, and from Temenos, in a regular and predictable way.
ABN Amro first implemented the Temenos T24 core banking platform – the forerunner to Temenos T24 Transact – for its corporate banking activities in 2009, Temenos Payments Hub in 2012 and Temenos WealthSuite for its international private banking business in 2015.
Friso Westra, Head of IT Development Core Banking International of ABN Amro said: “Thanks to Temenos’ innovative continuous-deployment product, we can gain greater product agility and improved time-to-value, accelerating the speed of innovation and making business changes rapidly. Temenos Continuous Deployment is to provide high levels of automation to support our agile development approach. Continuous Deployment will allow our developers to focus more time on the value of their deliverables spending less time coordinating testing and deployment with other teams.”
Max Chuard, Chief Executive Officer, Temenos, said: “I’m delighted that ABN Amro, a long standing customer, has now selected our Temenos Continuous Deployment SaaS product, as the bank is leading with DevOps tools and methodologies to accelerate its speed of software delivery and business innovation. We are entering a new era of banking where cloud-native, cloud-agnostic and advanced open API technologies are enabling the bank to dramatically reduce deployment time and as result massively cut down costs.”
Temenos is also launching a dedicated Deployment Centre of Excellence drawing on best practices from over 1000 go-lives and utilizing new tools, agile processes and methodologies to dramatically reduce the cost of deployment. This Centre of Excellence will help banks to industrialize the banking software deployments, with lower costs and faster time to market. Temenos has also launched a new implementation approach, Build and Renovate, that enables the larger banks to quickly build a new, fully digital stack, and to begin continuously migrating products and customers across from their legacy stack.
Temenos recently marked a major milestone with the launch of Temenos Infinity – a breakthrough digital front office product – and Temenos T24 Transact, the next generation in core banking. These new products further demonstrate a commitment to constant innovation, leveraging 25 years of functionality from 3,000 banks in more than 150 countries with the most advanced cloud-native, cloud-agnostic, API-first technology and design-led thinking.
– Ends –
About ABN Amro
ABN AMRO is a Dutch bank for retail, corporate and private banking clients. We are a relationship-driven, knowledgeable and digitally savvy bank, active in Northwest Europe and with expertise in selected sectors globally. Our purpose is Banking for better, for generations to come. Headquartered in Amsterdam, ABN AMRO employs around 19,000 people worldwide.
Please visit us at www.abnamro.com
Temenos AG (SIX: TEMN), headquartered in Geneva, is the world’s leader in banking software, partnering with banks and other financial institutions to transform their businesses and stay ahead of a changing marketplace. Over 3,000 firms across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic front office and core banking, payments, fund management and wealth management software products enabling banks to deliver both consistent, frictionless customer journeys and gain operational excellence. Temenos customers are proven to be more profitable than their peers: over a seven-year period, they enjoyed on average a 31% higher return on assets, a 36% higher return on equity and an 8.6 percentage point lower cost/income ratio than banks running legacy applications. For more information please visit www.temenos.com.
Temenos Global Public Relations
Tel: +1 610 232 2793
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetMedia Group takes over the management of financial platform Investing.com's European advertising space23.7.2019 08:07:00 CEST | Press release
NetMedia Group, media B2B leader in Europe in the world of business information, and Investing.com, second largest financial services and information platform in Europe, are to form a partnership, with NetMedia Group handling the sales of advertising space for Investing.com. With average traffic of over 21 million unique users totaling over 175 million sessions in 31 countries, Investing.com is one of the top three global financial websites and has the most downloaded financial management app. For Investing.com, the aim of the new partnership is to maximize digital advertising revenue through the NetMedia Group's European teams. NetMedia Group's goal is to expand its advertising services by offering a new vertical market for finance, in order to boost the range of services it has available to decision-makers for upper socio-professional target groups. About NetMedia Group: NetMedia Group is a B2B media group located in five countries across Europe; it employs nearly 150 staff members a
Frost & Sullivan Names Luminati the 2019 Global Market Leader in the Enterprise IP Proxy Networks Market23.7.2019 08:00:00 CEST | Press release
Luminati, the Israeli company that allows businesses to experience the web through the eyes of individual consumers throughout the world, today announced it has received a Market Leadership Award in the first independent analysis of the sector. Luminati’s enterprise IP proxy network (IPPN) services for global retailers, brand owners and advertising networks feature strongly in the report by analyst firm Frost & Sullivan. The report outlines a relatively new, but rapidly growing market and recognizes Luminati’s leading position in the provision of solutions that are increasingly important for businesses to remain competitive and compliant in the digital landscape. [S1] “The market for enterprise IP proxy network solutions is in its early growth stages, basically being invented by Luminati only a few years ago. With the more specialized targeting of customers by demographics and location, companies are finding it more difficult than ever to do competitive analysis and verify advertising,
LifeSpan BioSciences Releases Best-In-Class PathPlus™ Top Performing Immunohistochemistry Antibodies for Cancer Targets23.7.2019 08:00:00 CEST | Press release
LifeSpan BioSciences, Inc. (LSBio™), the industry leader in molecular pathology, today announced the first release of its PathPlus™ series of antibodies. These 565 antibodies were selected from among thousands tested and identified to be the best performing reagents for immunohistochemical detection of 200 high-value cancer targets in formalin-fixed paraffin-embedded human tissues. Antibody validation has become an industry roadblock as thousands of antibodies have become available to customers who face difficult choices in determining which antibodies are the best performers for each application, including immunohistochemistry, flow cytometry, ELISA, Western blot, or immunofluorescence. Antibodies that perform well in one assay, such as IHC, may not be the most specific reagent for another assay, such as flow cytometry. “Identifying the optimal reagents to use in their experiments is a pain point for researchers,” said LSBio CEO Heather Holemon. “There is a tremendous need to identify
IDEMIA Will Present Its H1 2019 Financial Results to Investors on July 30, 201923.7.2019 07:00:00 CEST | Press release
IDEMIA, the world leader in Augmented Identity, today announced that it will present its H1 2019 financial results to investors on Tuesday July 30, 2019. Yann Delabrière (CEO) and Laurent Lemaire (CFO) will be presenting the financial results and taking questions the same day at 3:30 pm CET (2:30 pm London Time / 9:30 am New York Time). For more information, please refer to our website: https://investors.idemia.com/ About IDEMIA IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whet
Gain Therapeutics SA Announces Award Notification of a €1.4M Grant Support From Eurostars-2 Together With the Institute for Research in Biomedicine and Neuro-Sys SAS After Having Scored 2nd Among 325 Eligible Applications23.7.2019 06:30:00 CEST | Press release
Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in central nervous system (CNS) diseases, today announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Università della Svizzera italiana (USI) and Neuro-Sys SAS in Gardanne (France), it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency. This grant will further strengthen Gain Therapeutics’s novel therapeutic approach for targeting rare diseases in the CNS, where lysosomal misfolded enzymes lead to sever clinical phenotypes, where no treatment is available and/or high unmet medical needs still do afflict patients, families and carers. This funding will support the development of the drugs portfolio of Gain Therapeutics for the
iBASIS Accelerates Growth With JC Geha as Chief Operating Officer23.7.2019 06:00:00 CEST | Press release
iBASIS, provider of communications solutions for operators and digital players worldwide, today announced the appointment of JC Geha as its COO. He will take his new post effective August 1, and be based at iBASIS’ headquarters in Lexington, Massachusetts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005757/en/ JC Geha (Photo: Business Wire) Formerly Senior Vice President, Head of International Technology and Services for Deutsche Telekom, and of Managed Services for Ericsson, Geha brings to iBASIS an impressive track record of profitable growth, technology and digital transformation expertise. His expertise spans 25 years of deep global industry relationships across the United States, Europe, Middle East, and Africa. Geha will lead iBASIS’ global operations, engineering, IT, and product development. He will report to iBASIS’ CEO and founder of the Group Tofane Global, Alexandre Pébereau, with the responsibility of g